Literature DB >> 28343727

Carbapenemase-producing Acinetobacter baumannii: An outbreak report with special highlights on economic burden.

J Gagnaire1, A Gagneux-Brunon1, A Pouvaret1, F Grattard2, A Carricajo2, H Favier1, A Mattei1, B Pozzetto2, C Nuti3, F Lucht1, P Berthelot4, E Botelho-Nevers1.   

Abstract

OBJECTIVE: We aimed to describe the management of a carbapenemase-producing Acinetobacter baumannii (CP-AB) outbreak using the Outbreak Reports and Intervention Studies of Nosocomial Infection (ORION) statement. We also aimed to evaluate the cost of the outbreak and simulate costs if a dedicated unit to manage such outbreak had been set-up.
METHODS: We performed a prospective epidemiological study. Multiple interventions were implemented including cohorting measures and limitation of admissions. Cost estimation was performed using administrative local data.
RESULTS: Five patients were colonized with CP-AB and hospitalized in the neurosurgery ward. The index case was a patient who had been previously hospitalized in Portugal. Four secondary colonized patients were further observed within the unit. The strains of A. baumannii were shown to belong to the same clone and all of them produced an OXA-23 carbapenemase. The closure of the ward associated with the discharge of the five patients in a cohorting area of the Infectious Diseases Unit with dedicated staff put a stop to the outbreak. The estimated cost of this 17-week outbreak was $474,474. If patients had been managed in a dedicated unit - including specific area for cohorting of patients and dedicated staff - at the beginning of the outbreak, the estimated cost would have been $189,046.
CONCLUSION: Controlling hospital outbreaks involving multidrug-resistant bacteria requires a rapid cohorting of patients. Using simulation, we highlighted cost gain when using a dedicated cohorting unit strategy for such an outbreak.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Acinetobacter baumannii; Bactéries productrices de carbapénémases; Carbapenemase-producing bacteria; Cost analysis; Disease outbreak; Épidémie; Évaluation médico-économique

Mesh:

Substances:

Year:  2017        PMID: 28343727     DOI: 10.1016/j.medmal.2017.02.006

Source DB:  PubMed          Journal:  Med Mal Infect        ISSN: 0399-077X            Impact factor:   2.152


  2 in total

1.  Development and validation of a time and motion guide to assess the costs of prevention and control interventions for nosocomial infections: A Delphi method among experts.

Authors:  Eric Tchouaket Nguemeleu; Sandra Boivin; Stephanie Robins; Drissa Sia; Kelley Kilpatrick; Sylvain Brousseau; Bruno Dubreuil; Catherine Larouche; Natasha Parisien
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

2.  What are acute NHS trusts in England doing to prevent the cross-border spread of carbapenem-resistant Enterobacteriaceae?

Authors:  Sharon Mawdsley
Journal:  J Infect Prev       Date:  2020-07-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.